大葉大學圖書館 |

mTOR inhibition for cancer therapy[electronic resource] :past, present and future /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.994
書名/作者:	mTOR inhibition for cancer therapy : past, present and future // edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
其他作者:	Mita, Monica.
出版者:	Paris : : Springer Paris :, 2016.
面頁冊數:	vi, 300 p. : : ill. (some col.), digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Cancer - Treatment.
標題:	Medicine.
標題:	Molecular biology.
標題:	Hematology.
標題:	Oncology.
標題:	Medicine & Public Health.
標題:	Molecular Medicine.
ISBN:	9782817804927
ISBN:	9782817804910
內容註:	Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
摘要、提要註:	This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
電子資源:	http://dx.doi.org/10.1007/978-2-8178-0492-7

mTOR inhibition for cancer therapy[electronic resource] :past, present and future /
mTOR inhibition for cancer therapypast, present and future /[electronic resource] :edited by Monica Mita, Alain Mita, Eric K. Rowinsky. - Paris :Springer Paris :2016. - vi, 300 p. :ill. (some col.), digital ;24 cm.

Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

ISBN: 9782817804927

Standard No.: 10.1007/978-2-8178-0492-7doiSubjects--Topical Terms:

338599
Cancer
--Treatment.

LC Class. No.: RC270.8

Dewey Class. No.: 616.994

mTOR inhibition for cancer therapy[electronic resource] :past, present and future /
LDR:02908nam a2200313 a 4500 001 455105
003 DE-He213
005 20160726141129.0
006 m d
007 cr nn 008maaau
008 161227s2016 fr s 0 eng d
020 $a 9782817804927 $q (electronic bk.)
020 $a 9782817804910 $q (paper)
024 7 $a 10.1007/978-2-8178-0492-7 $2 doi
035 $a 978-2-8178-0492-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270.8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.994 $2 23
090 $a RC270.8 $b .M939 2016
245 0 0 $a mTOR inhibition for cancer therapy $h [electronic resource] : $b past, present and future / $c edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
260 $a Paris : $b Springer Paris : $b Imprint: Springer, $c 2016.
300 $a vi, 300 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
520 $a This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
650 0 $a Cancer $x Treatment. $3 338599
650 0 $a Medicine. $3 373206
650 0 $a Molecular biology. $3 182854
650 0 $a Hematology. $3 381913
650 0 $a Oncology. $3 205017
650 1 4 $a Medicine & Public Health. $3 463493
650 2 4 $a Molecular Medicine. $3 463625
700 1 $a Mita, Monica. $3 653157
700 1 $a Mita, Alain. $3 653158
700 1 $a Rowinsky, Eric K. $3 653159
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-2-8178-0492-7
950 $a Medicine (Springer-11650)